New hope for CML patients: dasatinib shows promise in early treatment
NCT ID NCT00254423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug dasatinib can control chronic myeloid leukemia (CML) in its early chronic phase. 150 adults with newly diagnosed CML took dasatinib, and researchers measured how many achieved a major molecular response (very low levels of cancer genes) after 12 months. The goal was to see if dasatinib can keep the disease under control with manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine aims to shield transplant patients from deadly virus
- New combo therapy aims to deepen remission in chronic leukemia
- New vaccine aims to shield transplant patients from deadly virus
- Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
- New drug combo shows promise in controlling Early-Stage leukemia
- New hope for leukemia patients who failed standard treatments